@prefix chebi: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix hasPart: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix entrez: . @prefix ProteinComplex: . @prefix go: . @prefix hasAgent: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasPart: chebi:9168, sub:_2, sub:_3; a ProteinComplex: . sub:_2 geneProductOf: hgnc:3711; a Protein: . sub:_3 geneProductOf: entrez:2475; a Protein: . sub:_4 hasAgent: sub:_5; a go:0016301 . sub:_5 geneProductOf: entrez:2475; a Protein: . sub:_6 occursIn: species:9606; rdf:object sub:_4; rdf:predicate belv:decreases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "complex(a(SCHEM:Sirolimus),p(HGNC:FKBP1A),p(EGID:2475)) -| kin(p(EGID:2475))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_8; pav:version "20131211" . sub:_7 prov:value "This finding lead Chen et al. to propose a model for the action of rapamycin whereby rapamycin/FKBP12 binds to mTOR, preventing interaction with PA (3, 6). Consistent with the proposal that the rapamycin/FKBP12 complex acts competitively with PA, elevated PLD activity in human breast cancer cells increased the concentration of rapamycin required to suppress mTOR"; prov:wasQuotedFrom pubmed:17210675 . sub:_8 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:17210675; prov:wasDerivedFrom beldoc:, sub:_7 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:07.966+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }